Business
Cogent Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Updates
Andrew Robbins appointed President, CEO and Director Final results from PLX9486 + sunitinib Phase 1/2 study in GIST patients selected for oral presentation at
About this update from Cogent Biosciences, Inc.
[{"type":"text","content":"Andrew Robbins appointed President, CEO and Director\n Final results from PLX9486 + sunitinib Phase 1/2 study in GIST patients selected for oral presentation at Connective Tissue Oncology Society (CTOS) 2020 meeting\n Ended quarter with $129.4 million in cash, including proceeds from $104.4M Series A preferred stock private placement\n\n\nCAMBRIDGE, Mass., Nov. 9, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced financial results for the third quarter ended September 30, 2020 and provided several corporate updates.\n\n \n \n \n \n \n \n\n \n\"Over the past quarter, Cogent Biosciences has made tremendous progress establishing a clear strategy and focus that positions us as an emerging leader in the field of precision medicines for patients with genetically driven diseases,\" said Andrew Robbins, President and CEO of Cogent Biosciences. \"We are excited by the potential of our lead program, PLX9486, and look forward to presenting final clinical data from its Phase 1/2 study in GIST patients at CTOS 2020. We look forward to initiating new clinical trials of PLX9486 in patients with systemic mastocytosis and GIST in 2021, beginning in 1H 2021 with a trial of PLX9486 in advanced systemic mastocytosis (ASM) patients.\"\nRecent Program and Corporate Highlights\nAndrew Robbins appointed President, CEO and Director Mr. Robbins is an accomplished executive with extensive commercial, development, and strategic leadership experience during a 20-year career in the pharmaceutical industry, with a specific focus on oncology and hematology products. Most recently, as COO of Array Biopharma, he led the successful launch of MEKTOVI® (binimetinib) and BRAFTOVI® (encorafenib) for BRAF-mutant metastatic melanoma patients. \nPLX9486 + sunitinib GIST Phase 1/2 trial selected for CTOS 2020 oral presentation Title: The Potent and Selective Kit Inhibitor PLX9486 Dosed in Combination with Sunitinib Demonstrates Promising Progression Free Survival (PFS) in Patients with Advanced Gastrointestinal Stromal Tumor (GIST): Final Results of a Phase 1/2 Study Date: Friday, November 20, 2020 from 11:30 a.m. – 12:30 p.m. ETPresenter: Jonathan Trent, M.D., Ph.D., University of Miami Health System, Sylvester Comprehensive Cancer Center \nCog...